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The sensitization of patients to human leukocyte antigens prior to heart transplantation is increasingly being
recognized as an important challenge both before and after the transplant, and the effects of sensitization on
clinical outcomes are just beginning to be understood. Many patients are listed with the requirement of a
negative prospective or virtual crossmatch prior to accepting a donor organ. This strategy has been associated
with both longer waitlist times and higher waitlist mortality. An alternative approach is to transplant across a
potentially positive crossmatch while utilizing strategies to decrease the significance of the human leukocyte
antigen antibodies. This review will examine the challenges and the impact of sensitization on pediatric
patients prior to and following heart transplantation.
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The production of antibodies to human leukocyte antigen
(HLA) prior to transplantation is increasingly being recog-
nized as an important contributor to clinical outcomes in all
solid organ transplants. The role of the anti-HLA antibodies
was first recognized in kidney transplantation over 40 years
ago, and knowledge of their significance spread to the
transplantation of other solid organs in subsequent years
(1). This review will primarily focus on the issues associated
with sensitization in pediatric heart transplantation, with
some references to the other solid organ transplants.
Although a detailed description of the development of
these antibodies and the methods used for screening is
beyond the scope of this chapter, a framework will be
provided on which the rest of the discussion will occur. For
readers interested in further details on this topic, there are
some excellent recently published reviews (2,3).
& ANTI-HLA ANTIBODIES
Anti-HLA antibodies are antibodies directed against
antigens on Class I and Class II major histocompatibility
complexes. Class I molecules are found on all nucleated
cells in the body, and Class II expression is observed
predominantly on antigen-presenting cells and activated
endothelial cells (3-5). Anti-HLA antibodies can form prior
to transplantation in response to exposure to foreign
antigens. There are a number of situations that place a
child at risk of developing anti-HLA antibodies prior to
transplantation, with some of these being common to all
solid organ transplants and others being organ-specific.
Common risk factors for the development of anti-HLA
antibodies include the transfusion of blood products
(especially those that contain leukocytes and platelets),
previous organ transplantation, and a history of pregnancy
(6,7). Risk factors that are unique to the cardiac population
include previous cardiac surgery, especially surgery that
requires exposure to homograft materials for surgical
reconstruction, and the implantation of ventricular assist
devices for mechanical support (6,8-12).
& ANTIBODY TESTING
The presence and degree of anti-HLA antibody develop-
ment is an important part of the pretransplant evaluation
for a potential transplant candidate. HLA antibody screen-
ing is performed to determine the presence or absence of
HLA antibodies and, with more recent testing, the HLA
target and titers of these antibodies. Anti-HLA antibodies
can be detected using HLA antigens that are either cell-
based or part of a solid-phase assay (non-cell based) (3,13).
Cell-based strategies
Class I HLA molecules can be found on the intact cell
membrane of either T- or B-lymphocytes, with Class II
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molecules being limited to B-lymphocytes. These cells
provide the target antigens for the detection of anti-HLA
antibodies in cell-based assays. Cell-based assays may rely
on the binding of complement, as in the Complement-
Dependent Cytotoxicity (CDC) assay, to determine the
presence of HLA antibodies, or they can be conducted
independent of the binding of complement, such as in flow
cytometry (3). The CDC assay determines the percentage of
lymphocytes that undergo cell death when a patient’s serum
is added in the presence of complement. Flow cytometry
avoids the need for complement, as fluorescently tagged
anti-human globulin is used to detect the presence of anti-
HLA antibodies bound to the lymphocyte cell membrane.
These tests can be used to determine the percentage of cell
samples from a given population to which a recipient would
react (panel reactive antibody) and in turn represent the
HLA antigens that would be present in a donor pool from
the same population (3). Both CDC assays and flow
cytometry can also be used to determine whether a recipient
has antibodies to a particular donor (crossmatch) and
therefore help to predict the existence of a potential risk of
antibody-mediated rejection if that organ is transplanted (3).
Cell-based assays range in sensitivity, with CDC methods
being the least sensitive and flow cytometry being the most
sensitive (2,3,14). These assays can result in both false
positive and false negative results and do not allow for the
determination of antibody specificity (2,3,15).
Solid-phase strategies
Recent developments have led to the creation of solid-
phase assays. These assays utilize HLA antigens that are
bound to a matrix and are not associated with a cell
membrane. These solid-phase assays can be performed with
soluble or recombinant HLA antigens bound to either
plates (ELISA) or microbeads (flow cytometry or LuminexH
multiplex platform) (3,13,16). These technologies have the
advantage of not only determining the presence of HLA
antibodies but also the class and specificity. A Panel Reactive
Antibody (PRA) can be calculated using the known antigens
in a donor pool and the antibodies detected by the solid-
phase assay. Solid-phase assays are more sensitive than cell-
based assays, with the level of sensitivity increasing from
ELISA to flow-based technology. Unlike cell-based assays,
these methods do not detect non-HLA antibodies and are
unable to indicate whether an antibody has the capabilities of
binding complement. However, these assays can detect anti-
HLA antibodies below the threshold for a positive cross-
match (2,3,14,16). This level of sensitivity sometimes makes
interpretation difficult because the clinical relevance of some
of the antibodies that are detected remains unclear (3).
In clinical practice, the above information obtained
pretransplant from the HLA lab is typically represented
by the panel-reactive antibody (PRA) results. This number
reflects the percentage of HLA antigens in a given donor
population for which a recipient has antibodies. In general,
a patient is considered to be sensitized if either the Class I
or Class II PRA is $10%.
The HLA lab can also provide valuable information
regarding recipient-donor matching at the time of potential
donor evaluation, especially in the setting of living-related
transplantation (e.g., kidney and liver), wherein a prospec-
tive crossmatch is performed during the assessment to
determine the suitability of a particular donor-recipient
pair. This technique requires the incubation of donor tissue
with recipient serum to determine whether the antibodies
bind. This can be performed by a CDC assay or flow
cytometry. The biggest limitations to applying prospective
crossmatching to deceased donor transplantation, for
example, to heart transplantation, is the amount of time
that it takes and the need for donor samples. An alternative
option that addresses these issues is a virtual crossmatch. A
virtual crossmatch is not a laboratory test but rather is a
comparison of the known anti-HLA antibody specificities
detected by solid-phase testing and the known donor HLA
typing; using this approach makes it possible to avoid
donors with HLA types that the recipient has developed
antibodies to (3). Historically, the most common practice has
been to perform a retrospective crossmatch. In this scenario,
recipient serum and donor tissue are incubated after the
transplant has occurred to determine whether there is
evidence of antibodies against the donor. If the retrospective
crossmatch is positive, most programs adopt different
surveillance and management strategies to reduce the
burden of antibodies and the risk of antibody-mediated
rejection following transplantation.
& THE CLINICAL RELEVANCE OF ANTI-HLA
ANTIBODIES
Although debated in the past, it is now recognized that
both class I and class II antibodies have an impact on
outcomes posttransplantation. These antibodies have been
associated with rejection following transplantation in many
of the solid organs, including the kidney, liver, and lungs in
adult populations (17-20), and have also been shown to be
associated with decreased survival, graft loss, rejection, and
vascular thrombosis following pediatric kidney transplanta-
tion (21-23).
The literature regarding the impact of preformed anti-
HLA antibodies in pediatric heart transplantation remains
limited. However, it has been well established in the adult
heart transplant population that anti-HLA antibodies are
associated with decreased survival and an increase in
antibody-mediated cellular and chronic rejection (allograft
vasculopathy) (24-29).
Currently, anywhere from 15-30% of pediatric patients
listed for heart transplantation are sensitized (PRA$10%),
with this number increasing in recent years (11,12,30).
Earlier pediatric studies following heart transplantation
have reported inconsistent results with respect to the role of
elevated PRA on posttransplant outcomes. In a small cohort
of pediatric heart transplant recipients, Jacobs et al. reported
that an elevated CDC PRA did not affect 30-day survival
(25% vs. 7.9%, p= 0.178) but was associated with higher
overall mortality (31). Wright et al. further explored this
relationship by examining the impact of both an elevated
PRA and the retrospective crossmatch results. The authors’
analysis revealed no difference in graft survival between
those patients who exhibited elevated PRA results versus
those who were negative. However, when analyzed using
crossmatch results, the authors clearly demonstrated that
those patients with a positive retrospective crossmatch
exhibited a worse overall survival (p,0.015) despite no
difference in the time to cellular rejection, rejection grade, or
the number of rejection episodes (32). In their analysis, the
median time to graft loss was 15 months in those with a
positive crossmatch, and no grafts with a positive cross-
match survived beyond 58 months. In contrast, a number of
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smaller studies from other institutions reported that an
elevated PRA did not affect survival posttransplantation
(11,33).
Findings from the Pediatric Heart Transplant Study
group, a large multi-institutional prospective database,
concur with the findings of these smaller centers. These
groups demonstrated that 6-month survival posttransplant
was lower (77 vs. 93%) in those patients who exhibited a
PRA$50% compared with those with a PRA,10%. On
further analysis, recipients with a PRA$20% but a negative
prospective crossmatch exhibited similar survival to those
with a PRA,20%, but those with a PRA$20% and a positive
prospective crossmatch experienced a survival disadvan-
tage at 1-year posttransplant. Interestingly, this study did
not identify any difference in rejection outcomes or the
development of vasculopathy based on sensitization status
(12). In contrast, a single-center study has reported an
association with elevated HLA antibodies and the later
development of allograft vasculopathy (HR 2.76, CI 1.18-
6.45, p= 0.019) (11), and a more recent study has demon-
strated no increased risk of antibody-mediated rejection in
those with an elevated PRA but a negative prospective
crossmatch (33).
The approach to patients with anti-HLA antibodies has
varied over the years as research and understanding of this
complex topic has expanded. Currently, many pediatric
centers require a negative prospective or virtual crossmatch
prior to accepting a donor organ to avoid the risk of
antibody-mediated rejection and improve graft survival.
However, this strategy itself has its own limitations
(11,12,33,34). Feingold et al. (2007) have demonstrated, in
their single-center study, that the mean time to transplanta-
tion was longer for those patients who required a negative
prospective crossmatch (PRA .20%) and that there was a
higher proportion of patients who died by 1 year after
listing (22% vs. 8%, p= 0.055) (11). Similar findings were
reported in a larger multi-institutional study in which the
one-year waitlist mortality was 19% for those with a
PRA.50% compared with 9% for those patients with a
PRA,10% (12). Furthermore, using the Organ Procurement
and Transplant Network, the requirement for a prospective
crossmatch at the time of listing was associated with
longer waitlist times (248.7¡482.8 vs. 186.2¡504, p,
0.0001), an increase in the waitlist mortality (HR 1.32, CI
1.10 to 1.56, p= 0.003), and a decreased likelihood of
achieving transplantation. In addition, this listing strategy
was an independent predictor of waitlist mortality (HR 1.32,
CI 1.10-1.56, p= 0.003) (34).
Due to issues with the requirement of a negative
prospective crossmatch, some centers have developed
alternative strategies to decrease the antibody burden prior
to or at the time of transplantation. This has been under-
taken with the hope of improving posttransplant outcomes
and decreasing the number of waitlist deaths.
& PREVENTATIVE STRATEGIES
Prior to discussing strategies to address patients who are
sensitized at the time of listing, it is important to discuss
some strategies to prevent sensitization in patients who may
be listed for transplantation or may require transplantation
in the future. In patients with complex congenital heart
disease, especially those with hypoplastic left heart syn-
drome, the avoidance of homografts or alterations of
surgical materials to avoid antibody production may result
in less sensitization (35). Because a number of these patients
may require transplantation in the future due to a failing
Fontan circulation, these precautions may decrease the risk
of transplantation in this already high-risk, complex
population. For those patients awaiting transplantation,
avoiding exposure to HLA antigens is essential for the
prevention of sensitization. This can include limiting
platelet and plasma transfusions and using packed red
blood cells that have been processed to remove leukocytes
and platelets.
& PRE- AND POST- TRANSPLANT MANAGEMENT
For patients who already exhibit preformed anti-HLA
antibodies, there are a number of strategies that have been
employed prior to or following transplantation to mitigate
risk. The common goal of these strategies is to decrease the
burden of the antibodies present. The targets for these
strategies include removing preexisting antibodies and
preventing the further production of antibodies. Although
an exhaustive description of these strategies is beyond the
scope of this chapter, some of the current strategies will be
outlined.
Antibody removal can be achieved by plasma exchange
in the operating room or by plasmapheresis pre- or
posttransplant. Recently, protein-A immunoadsorption col-
umns have also been used to decrease the circulating HLA
antibodies without depleting all of the plasma components
(36-40). These strategies are rarely used alone and often are
combined with intravenous immunoglobulin (IVIG) and B-
cell–directed therapies. Intravenous immunoglobulin (IVIG)
has been used pretransplant for the purpose of desensitiza-
tion and posttransplant in patients with a positive cross-
match. The mechanism by which IVIG works in this
scenario remains unclear, but some proposed theories
include the modulation of antibody and cytokine produc-
tion, alteration of various signaling pathways, and comple-
ment inhibition (41,42).
Anti-B cell therapies have included the use of cyclopho-
sphamide and mycophenolate mofetil, which deplete
rapidly dividing cells and can result in decreased antibody
production by inhibiting B-cell proliferation. Additional B-
cell therapies include rituximab, which is a chimeric anti-
CD20 monoclonal antibody that targets CD20-expressing
cells. This antibody typically depletes CD20-expressing B-
cells but does not deplete mature plasma cells that produce
antibodies. Therefore, other agents that target plasma cells,
including alemtuzumab (campath 1H) and bortezomib,
have been proposed to fill this gap in the strategy to
decrease the production of anti-HLA antibodies.
Desensitization, although common in kidney transplanta-
tion, has been utilized less in heart transplantation. The goal
of desensitization is to decrease the HLA antibody load
prior to transplantation to decrease the risk of rejection in
the presence of antibodies. Various protocols have been
used, predominantly in adult heart transplantation, with a
combination of IVIG and rituximab with or without
plasmapheresis (43-45). A few reports of desensitization
pretransplant have also surfaced in heart transplant
candidates with the use of immunoabsorption columns
(36,37) and bortezomib (46). However, despite a limited
number of reports, there is evidence from adult studies that
a combination of plasmapheresis, IVIG, and rituximab
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pretransplant can decrease the circulating antibody loads
and increase the number of potential donors, with similar
long-term survival and risk of allograft vasculopathy when
compared with nonsensitized patients (45). In pediatrics, a
similar approach using IVIG and rituximab was used in 14
patients with a PRA.10% without plasmapheresis. There
was a significant reduction in the median calculated PRA in
8/14 patients. This strategy led to a median increase in the
percentage of acceptable donors from 10% to 85%. Of the
8 responders, 5 were transplanted with one positive cross-
match and no detectable rejection (47). Long-term outcome
data remain lacking.
Alternatively, some programs have opted to not desensi-
tize patients prior to transplant but rather to address
antibodies at the time of transplantation. Transplanting
across a positive crossmatch must be weighed against
waitlist mortality, posttransplant survival, and longer-term
issues. Although this approach has been associated with
increased risk, varying success rates have been reported in
the pediatric heart transplant population. The limited
number of pediatric donors and high waitlist mortality
has primarily driven this approach. Holt et al. reported their
experience with perioperative plasmapheresis, thymoglo-
bulin, and cyclophosphamide in 17 patients with PRA.10%
(48). Thirteen of these patients also exhibited a positive CDC
crossmatch. Survival at 1 and 3 years was 85% and 73%,
respectively, with these results being comparable to the
reported outcomes from the ISHLT registry (48). The
majority of these patients did experience early rejection;
with many having both recurrent and hemodynamically
significant episodes within the first 6 months posttransplant
(48). The Hospital for Sick Children subsequently published
their outcomes in transplanting sensitized patients. Their
protocol included intraoperative plasma exchange, induc-
tion with thymoglobulin, posttransplant plasmapheresis (in
those with a positive crossmatch), and a variety of B- and
T-cell therapies depending on the clinical situation. During
the study period from 1990-2006, 13 patients exhibited a
PRA$10%. Of these, 12 patients underwent plasmapheresis
posttransplant for a positive donor-specific crossmatch. This
cohort had a 3-month survival posttransplant of 89% with a
1-year survival of 71%. In the posttransplant period, 9
patients developed AMR, and 7 suffered $2R acute cellular
rejection, with only 1 patient experiencing hemodynamic
compromise due to rejection, which resulted in death. As
seen in the previous studies, no patients developed AMR
beyond 6 months posttransplantation (49).
Although these single-center studies have provided
useful information, it remains unclear whether these
findings can be improved upon or can be replicated in
other centers. Currently, there is a multicenter National
Institutes of Health Study examining a uniform strategy for
treating sensitized patients in which the first available organ
donor is accepted, regardless of the potential for a positive
donor-specific crossmatch (50). This trial will provide
further details about transplantation in this patient popula-
tion and could provide a framework for improving out-
comes in this ever-increasing population.
& FUTURE DIRECTIONS
Although the techniques used to detect anti-HLA
antibodies have improved, the significance and clinical
relevance of the antibodies detected remain unclear.
Recently, there have been many questions raised about the
role of anti-HLA antibodies that are unable to bind
complement, with the theory that the ability to bind
complement may be one of the key factors in the
determination of clinically relevant antibodies. Work at
Stanford University has led to the development of an assay
that can detect antibodies that bind the C1q component of
the complement cascade (51). This assay has been used in
the pediatric population and was found to detect a subset of
patients at risk of developing AMR early after transplanta-
tion (51). This technique, though it requires further valida-
tion, does hold some promise for helping those practicing in
the field of transplant to further understand the role of anti-
HLA antibodies.
Sensitization is an issue that is increasing in frequency in
the pediatric heart transplant population. Listing these
patients for transplant with the requirement for a negative
virtual or prospective crossmatch may decrease the risks
posttransplant at the expense of increased mortality on the
waitlist. Strategies to improve both the short-term and
longer-term outcomes of those transplanted with a positive
crossmatch are being explored with the hope of decreasing
waitlist mortality and improving outcomes posttransplant
in this patient population.
& AUTHOR CONTRIBUTIONS
Conway J performed the research and wrote the manuscript, and
Dipchand A edited the manuscript.
& REFERENCES
1. Patel R, Terasaki PI. Significance of the Positive Crossmatch Test in
Kidney Transplantation. N Engl J Med. 1969;280(14):735-9.
2. Zeevi A, Girnita A, Duquesnoy R. HLA antibody analysis: sensitivity,
specificity, and clinical significance in solid organ transplantation.
Immunol Res. 2006;36(1-3):255-64, http://dx.doi.org/10.1385/IR:36:1:
255.
3. Tinckam K. Histocompatibility methods. Transplant Rev (Orlando).
2009;23(2):80-93, http://dx.doi.org/10.1016/j.trre.2009.01.001.
4. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human
kidney HLA-DR-expressing renal microvascular endothelial cells:
characterization, isolation, and regulation of MHC class II expression.
J Am SocNephrol. 2003;14(5):1336-48, http://dx.doi.org/10.1097/01.ASN.
0000061778.08085.9F.
5. Taflin C, Charron D, Glotz D, Mooney N. Immunological function of the
endothelial cell within the setting of organ transplantation. Immunol
Lett. 2011;139(1-2):1-6, http://dx.doi.org/10.1016/j.imlet.2011.04.014.
6. Shaddy RE, Fuller TC. The sensitized pediatric heart transplant
candidate: causes, consequences, and treatment options. Pediatr
Transplant. 2005;9(2):208-14, http://dx.doi.org/10.1111/j.1399-3046.2005.
00262.x.
7. Scornik JC, Pfaff WW, Howard RJ, Fennell RS, 3rd, Ramos E, Peterson JC,
et al. Increased antibody responsiveness to blood transfusions in
pediatric patients. Transplantation. 1994;58(12):1361-5.
8. Shaddy RE, Fuller TC, Anderson JB, Lambert LM, Brinkman MK,
Profaizer T, et al. Mycophenolic mofetil reduces the HLA antibody
response of children to valved allograft implantation. Ann Thorac Surg.
2004;77(5):1734-9, http://dx.doi.org/10.1016/j.athoracsur.2003.10.047.
9. Yang J, Schall C, Smith D, Kreuser L, Zamberlan M, King K, et al. HLA
sensitization in pediatric pre-transplant cardiac patients supported by
mechanical assist devices: the utility of Luminex. J Heart Lung Transplant.
2009;28(2):123-9, http://dx.doi.org/10.1016/j.healun.2008.11.908.
10. O’Connor MJ, Menteer J, Chrisant MR, Monos D, Lind C, Levine S, et al.
Ventricular assist device-associated anti-human leukocyte antigen anti-
body sensitization in pediatric patients bridged to heart transplantation.
J Heart Lung Transplant. 2010;29(1):109-16, http://dx.doi.org/10.1016/j.
healun.2009.08.028.
11. Feingold B, Bowman P, Zeevi A, Girnita AL, Quivers ES, Miller SA, et al.
Survival in allosensitized children after listing for cardiac transplanta-
tion. J Heart Lung Transplant. 2007;26(6):565-71, http://dx.doi.org/10.
1016/j.healun.2007.03.015.
12. Mahle WT, Tresler MA, Edens RE, Rusconi P, George JF, Naftel DC, et al.
Allosensitization and outcomes in pediatric heart transplantation.
Sensitization and Pediatric Heart Transplant
Conway J and Dipchand AI
CLINICS 2014;69(S1):17-21
20
The J Heart Lung Transplant. 2011;30(11):1221-7, http://dx.doi.org/10.
1016/j.healun.2011.06.005.
13. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA
antibody detection: technology emulating biology. Immunol Res. 2004;
29(1-3):41-54, http://dx.doi.org/10.1385/IR:29:1-3:041.
14. Gebel HM, Bray RA. Sensitization and sensitivity: defining the
unsensitized patient. Transplantation. 2000;69(7):1370-4, http://dx.doi.
org/10.1097/00007890-200004150-00027.
15. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after
solid organ transplantation. Transplantation. 2000;69(3):319-26, http://
dx.doi.org/10.1097/00007890-200002150-00001.
16. Girnita AL, Webber SA, Zeevi A. Anti-HLA alloantibodies in pediatric
solid organ transplantation. Pediatr Transplant. 2006;10(2):146-53, http://
dx.doi.org/10.1111/j.1399-3046.2005.00425.x.
17. Girnita AL, McCurry KR, Iacono AT, Duquesnoy R, Corcoran TE, Awad
M, et al. HLA-specific antibodies are associated with high-grade and
persistent-recurrent lung allograft acute rejection. J Heart Lung
Transplant. 2004;23(10):1135-41, http://dx.doi.org/10.1016/j.healun.2003.
08.030.
18. Toresan R, Manfro RC, Proenca MC, Veronese FJ, Salim PH, da Silva
DM, et al. Association between the presence of anti-HLA antibodies with
acute rejection and chronic allograft nephropathy in the first year after
kidney transplantation. Transplant Proc. 2008;40(3):718-9, http://dx.doi.
org/10.1016/j.transproceed.2008.02.050.
19. Girnita AL, Duquesnoy R, Yousem SA, Iacono AT, Corcoran TE,
Buzoianu M, et al. HLA-specific antibodies are risk factors for
lymphocytic bronchiolitis and chronic lung allograft dysfunction.
Am J Transplant. 2005;5(1):131-8.
20. Ionescu DN, Girnita AL, Zeevi A, Duquesnoy R, Pilewski J, Johnson B,
et al. C4d deposition in lung allografts is associated with circulating anti-
HLA alloantibody. Transpl Immunol. 2005;15(1):63-8, http://dx.doi.org/
10.1016/j.trim.2005.05.001.
21. Fine RN, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH,
Korsch BM. Renal retransplantation in children. J Pediatr. 1979;95(2):244-
8.
22. Dalla Vecchia LK, Book BK, Milgrom ML, Jindal RM, Leapman SB, Filo
RS, et al. Predictive value of enzyme-linked immunosorbent assay-
detected IgG anti-HLA antibodies for pediatric renal allograft rejection.
Transplantation. 1997;64(12):1744-7, http://dx.doi.org/10.1097/00007890-
199712270-00021.
23. Emonds MP, Herman J, Dendievel J, Waer M, Van Damme-Lombaerts R.
Evaluation of anti-human leukocyte antigen allo-immunization in
pediatric cadaveric kidney transplantation. Pediatr Transplant. 2000;
4(1):6-11, http://dx.doi.org/10.1034/j.1399-3046.2000.00075.x.
24. Lavee J, Kormos RL, Duquesnoy RJ, Zerbe TR, Armitage JM, Vanek M,
et al. Influence of panel-reactive antibody and lymphocytotoxic cross-
match on survival after heart transplantation. J Heart Lung Transplant.
1991;10(6):921-9.
25. Di Filippo S, Girnita A, Webber SA, Tsao S, Boyle GJ, Miller SA, et al.
Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac
allograft outcome. Hum Immunol. 2005;66(5):513-8, http://dx.doi.org/
10.1016/j.humimm.2004.12.008.
26. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA,
Conte JV. Influence of pretransplant panel-reactive antibody on out-
comes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg.
2007;84(5):1556-62, http://dx.doi.org/10.1016/j.athoracsur.2007.05.095.
27. Reinsmoen NL, Nelson K, Zeevi A. Anti-HLA antibody analysis and
crossmatching in heart and lung transplantation. Transpl Immunol.
2004;13(1):63-71, http://dx.doi.org/10.1016/j.trim.2004.01.005.
28. Kobashigawa JA, Sabad A, Drinkwater D, Cogert GA, Moriguchi JD,
Kawata N, et al. Pretransplant panel reactive-antibody screens. Are
they truly a marker for poor outcome after cardiac transplantation?
Circulation. 1996;94(9 Suppl):II294-7.
29. Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH. The effect of
panel reactive antibodies and the donor specific crossmatch on graft
survival after heart and heart-lung transplantation. Transpl Immunol.
1993;1(1):60-5, http://dx.doi.org/10.1016/0966-3274(93)90060-L.
30. Kirk R, Dipchand AI, Edwards LB, Kucheryavaya AY, Benden C,
Christie JD, et al. The registry of the International Society for Heart and
Lung Transplantation: fifteenth pediatric heart transplantation report—
2012. J Heart Lung Transplant. 2012;31(10):1065-72, http://dx.doi.org/
10.1016/j.healun.2012.08.001.
31. Jacobs JP, Quintessenza JA, Boucek RJ, Morell VO, Botero LM, Badhwar
V, et al. Pediatric cardiac transplantation in children with high panel
reactive antibody. Ann Thorac Surg. 2004;78(5):1703-9, http://dx.doi.
org/10.1016/j.athoracsur.2004.03.031.
32. Wright EJ, Fiser WP, Edens RE, Frazier EA, Morrow WR, Imamura M,
et al. Cardiac transplant outcomes in pediatric patients with pre-formed
anti-human leukocyte antigen antibodies and/or positive retrospective
crossmatch. J Heart Lung Transplant. 2007;26(11):1163-9, http://dx.doi.
org/10.1016/j.healun.2007.07.042.
33. Scott V, Williams RJ, Levi DS. Outcomes of cardiac transplantation in
highly sensitized pediatric patients. Pediatr Cardiol. 2011;32(5):615-20,
http://dx.doi.org/10.1007/s00246-011-9928-5.
34. Feingold B, Park SY, Comer DM, Bryce CL, Webber SA. Listing
requirements for a prospective crossmatch in pediatric heart transplan-
tation: analysis of organ procurement and transplantation network data
from 1996 to 2009. J Heart Lung Transplant. 2012;31(10):1143-4, http://
dx.doi.org/10.1016/j.healun.2012.08.006.
35. Laing BJ, Ross DB, Meyer SR, Campbell P, Halpin AM, West LJ, et al.
Glutaraldehyde treatment of allograft tissue decreases allosensitization
after the Norwood procedure. J Thorac Cardiovasc Surg. 2010;139
(6):1402-8, http://dx.doi.org/10.1016/j.jtcvs.2009.12.034.
36. Bucin D, Johansson S, Malm T, Jogi P, Johansson J, Westrin P, et al. Heart
transplantation across the antibodies againstHLAandABO. Transpl Int. 2006;
19(3):239-44, http://dx.doi.org/10.1111/j.1432-2277.2005.00260.x.
37. Bucin D, Johansson S, Lindberg LO. Heart transplantation across
antibodies against human leukocyte antigen and ABO-post-transplant
follow-up of donor reactive antibodies. Xenotransplantation. 2006;
13(2):101-4, http://dx.doi.org/10.1111/j.1399-3089.2006.00276.x.
38. Pretagostini R, Berloco P, Poli L, Cinti P, Di Nicuolo A, De Simone P, et al.
Immunoadsorption with protein A in humoral rejection of kidney
transplants. ASAIO J. 1996;42(5):M645-8.
39. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K,
et al. Peritransplant immunoadsorption: a strategy enabling transplantation
in highly sensitized crossmatch-positive cadaveric kidney allograft
recipients. Transplantation. 2005;79(6):696-701, http://dx.doi.org/10.1097/
01.TP.0000148732.26761.FA.
40. Bartel G, Wahrmann M, Regele H, Kikic Z, Fischer G, Druml W, et al.
Peritransplant immunoadsorption for positive crossmatch deceased
donor kidney transplantation. Am J Transplant. 2010;10(9):2033-42.
41. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous
immunoglobulin. Annu Rev Immunol. 2008;26:513-33, http://dx.doi.org/
10.1146/annurev.immunol.26.021607.090232.
42. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV,
et al. Intravenous immunoglobulins—understanding properties and
mechanisms. Clin Exp Immunol. 2009;158 Suppl 1:2-13, http://dx.doi.
org/10.1111/j.1365-2249.2009.04022.x.
43. McIntyre JA, Higgins N, Britton R, Faucett S, Johnson S, Beckman D, et al.
Utilization of intravenous immunoglobulin to ameliorate alloantibodies
in a highly sensitized patient with a cardiac assist device awaiting heart
transplantation. Fluorescence-activated cell sorter analysis. Transplantation.
1996;62(5):691-3, http://dx.doi.org/10.1097/00007890-199609150-00027.
44. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al.
Evaluation of intravenous immunoglobulin as an agent to lower
allosensitization and improve transplantation in highly sensitized adult
patients with end-stage renal disease: report of the NIH IG02 trial. J Am
Soc Nephrol. 2004;15(12):3256-62, http://dx.doi.org/10.1097/01.ASN.
0000145878.92906.9F.
45. Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK,
Davis SN, et al. The long-term outcome of treated sensitized patients
who undergo heart transplantation. Clin Transplant. 2011;25(1):E61-7,
http://dx.doi.org/10.1111/j.1399-0012.2010.01334.x.
46. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J.
Reduction of alloantibodies via proteasome inhibition in cardiac
transplantation. J Heart Lung Transplant. 2011;30(12):1320-6, http://dx.
doi.org/10.1016/j.healun.2011.08.009.
47. Schumacher KR, Ramon DS, Kamoun M, Caruthers R, Gajarski RJ. HLA
desensitization in pediatric heart transplant candidates: efficacy of
rituximab and IVIg. J Heart Lung Transplant. 2012;31(9):1041-2, http://
dx.doi.org/10.1016/j.healun.2012.05.009.
48. Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston
CB, et al. Mortality and morbidity in pre-sensitized pediatric heart
transplant recipients with a positive donor crossmatch utilizing peri-
operative plasmapheresis and cytolytic therapy. J Heart Lung
Transplant. 2007;26(9):876-82, http://dx.doi.org/10.1016/j.healun.2007.
07.011.
49. Pollock-BarZiv SM, den Hollander N, Ngan BY, Kantor P, McCrindle B,
West LJ, et al. Pediatric heart transplantation in human leukocyte antigen
sensitized patients: evolving management and assessment of intermedi-
ate-term outcomes in a high-risk population. Circulation. 2007;116(11
Suppl):I172-8.
50. Trials.gov C. Allo-antibodies in Pediatric Heart Transplantation.
ClinicalTrials.gov Identifier: NCT01005316 [cited 2012 Nov 12]; Avail-
able from: http://www.clinicaltrials.gov/ct2/show/NCT01005316?term
= ctotc-04&rank= 1.
51. Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical
usefulness of a novel C1q assay to detect immunoglobulin G antibodies
capable of fixing complement in sensitized pediatric heart transplant
patients. J Heart Lung Transplant. 2011;30(2):158-63, http://dx.doi.org/
10.1016/j.healun.2010.08.020.
CLINICS 2014;69(S1):17-21 Sensitization and Pediatric Heart Transplant
Conway J and Dipchand AI
21
